STOCK TITAN

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Vivani Medical (Nasdaq: VANI), a biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York. CEO Adam Mendelsohn will host one-on-one investor meetings and deliver a company overview presentation on September 11, 2024, at 10 a.m. ET in the Adams Room at Lotte New York Palace.

The presentation will be accessible via webcast and on Vivani's website. This event provides an opportunity for Vivani to showcase its innovative drug delivery technology to potential investors and industry professionals, potentially impacting its market position and investor relations.

Vivani Medical (Nasdaq: VANI), una società biofarmaceutica che sviluppa impianti farmaceutici sottocutanei miniaturizzati e a lunga durata, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright, che si svolgerà dal 9 all'11 settembre 2024 a New York. Il CEO Adam Mendelsohn ospiterà incontri individuali con gli investitori e presenterà una panoramica dell'azienda l'11 settembre 2024, alle 10:00 ET nella sala Adams presso il Lotte New York Palace.

La presentazione sarà accessibile tramite webcast e sul sito web di Vivani. Questo evento offre a Vivani l'opportunità di mettere in mostra la sua innovativa tecnologia di somministrazione dei farmaci a potenziali investitori e professionisti del settore, con la possibilità di influenzare la sua posizione di mercato e le relazioni con gli investitori.

Vivani Medical (Nasdaq: VANI), una compañía biofarmacéutica que desarrolla implantes de medicamentos subdérmicos miniatura y de acción prolongada, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York. El CEO Adam Mendelsohn será el encargado de reuniones uno a uno con los inversionistas y presentará una visión general de la empresa el 11 de septiembre de 2024, a las 10 a.m. ET en la sala Adams en el Lotte New York Palace.

La presentación será accesible a través de webcast y en el sitio web de Vivani. Este evento ofrece a Vivani la oportunidad de mostrar su innovadora tecnología de entrega de medicamentos a posibles inversores y profesionales de la industria, lo que podría afectar su posición en el mercado y sus relaciones con los inversionistas.

Vivani Medical (Nasdaq: VANI), 미니어처 초장기 지속형 피하 약물 이식물을 개발하는 생명공학 회사,는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CEO 아담 멘델손은 1:1 투자자 미팅을 진행하고, 2024년 9월 11일 오전 10시 ET에 Lotte New York Palace의 Adams Room에서 회사 개요 발표를 진행할 예정입니다.

이번 발표는 웹캐스트와 Vivani의 웹사이트를 통해 접속할 수 있습니다. 이번 행사에서는 Vivani가 잠재 투자자 및 업계 전문가들에게 혁신적인 약물 전달 기술을 선보일 수 있는 기회를 제공하며, 이는 시장 위치 및 투자자 관계에 영향을 미칠 수 있습니다.

Vivani Medical (Nasdaq: VANI), une société biopharmaceutique développant des implants médicamenteux sous-cutanés miniatures et à action prolongée, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur l'Investissement H.C. Wainwright qui se déroulera du 9 au 11 septembre 2024 à New York. Le PDG Adam Mendelsohn animera des réunions individuelles avec des investisseurs et présentera un aperçu de l'entreprise le 11 septembre 2024, à 10h00 ET dans la salle Adams du Lotte New York Palace.

La présentation sera accessible par webinaire et sur le site Web de Vivani. Cet événement offre à Vivani la possibilité de mettre en avant sa technologie innovante de délivrance de médicaments à des investisseurs potentiels et des professionnels de l'industrie, pouvant potentiellement influencer sa position sur le marché et ses relations avec les investisseurs.

Vivani Medical (Nasdaq: VANI), ein biopharmazeutisches Unternehmen, das Miniatur- und langwirksame subdermale Arzneimittelimplantate entwickelt, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 in New York angekündigt. CEO Adam Mendelsohn wird Einzelgespräche mit Investoren führen und am 11. September 2024 um 10 Uhr ET im Adams Room des Lotte New York Palace eine Unternehmenspräsentation halten.

Die Präsentation wird über Webcast und auf der Website von Vivani zugänglich sein. Diese Veranstaltung bietet Vivani die Gelegenheit, seine innovative Arzneimittelverabreichungstechnologie potenziellen Investoren und Fachleuten der Branche vorzustellen, was möglicherweise Auswirkungen auf seine Marktstellung und Investorenbeziehungen hat.

Positive
  • None.
Negative
  • None.

ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York.

Vivani’s Chief Executive Officer, Adam Mendelsohn, Ph.D., will host one-on-one meetings with investors at the Conference in addition to providing an overview of the Company. Details of this presentation are as follows:

Date: Wednesday, September 11, 2024
Time: 10-10:30 a.m. Eastern Time
Location: Adams Room (Fourth floor), Lotte New York Palace, New York, NY

The Company presentation will be available via webcast starting at 10 a.m. ET on September 11 at the following link: https://journey.ct.events/view/a00c80c3-0668-4058-b4ca-4aad48978600.

The presentation will also be available on the Company’s website under the “News & Events” tab of the Vivani Investor page: https://investors.vivani.com/investors/news-events.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve tolerance to their medication. Vivani’s lead program, NPM-115, will evaluate a miniature, six-month, subdermal, GLP-1 (exenatide) implant for chronic weight management in obese or overweight patients. Vivani’s emerging pipeline also includes NPM-139 (semaglutide implant) which is also under development for chronic weight management in obese and overweight patients. NPM-139 has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s clinical program which will evaluate its six-month, subdermal exenatide implant for the treatment of type 2 diabetes. Both NPM-115 and NPM-119 will evaluate exenatide implants with a higher-dose associated with NPM-115 for chronic weight management in obese or overweight patients. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the initiation of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, and NPM-119. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities, including Vivani’s ability to commence clinical development of NPM-115; risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 26, 2024, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:

Donald Dwyer

Chief Business Officer

info@vivani.com

(415) 506-8462



Investor Relations Contact:

Jami Taylor

Investor Relations Advisor

investors@vivani.com

(415) 506-8462



Media Contact:

Sean Leous

ICR Westwicke

sean.leous@westwicke.com

(646) 866-4012

Source: Vivani Medical, Inc.

FAQ

When and where is Vivani Medical (VANI) presenting at the H.C. Wainwright Global Investment Conference?

Vivani Medical (VANI) is presenting on Wednesday, September 11, 2024, from 10-10:30 a.m. Eastern Time in the Adams Room (Fourth floor) at Lotte New York Palace, New York, NY.

How can investors access Vivani Medical's (VANI) presentation at the H.C. Wainwright conference?

Investors can access Vivani Medical's (VANI) presentation via webcast starting at 10 a.m. ET on September 11, 2024, using the provided link or through the 'News & Events' tab on Vivani's Investor page.

What type of technology is Vivani Medical (VANI) developing?

Vivani Medical (VANI) is developing miniature, ultra long-acting, subdermal drug implants for innovative drug delivery.

Who will represent Vivani Medical (VANI) at the H.C. Wainwright Global Investment Conference?

Adam Mendelsohn, Ph.D., Chief Executive Officer of Vivani Medical (VANI), will represent the company at the conference, hosting one-on-one meetings with investors and providing a company overview.

Vivani Medical, Inc.

NASDAQ:VANI

VANI Rankings

VANI Latest News

VANI Stock Data

69.30M
30.22M
52.51%
10.47%
1.37%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ALAMEDA